Patent SG-11201901466P-A (SG)
Title: A method of identifying risk of cancer and therapeutic options
Inventor: YU QIANG
IPC: C12Q1/68
Filed: 2017-09-07
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 15 March 2018 (15.03.2018) WIP0 I PCT ill~~~~~~~~ 011101010VIIIOH olo olo mull oil ioo Immo oimIE (10) International Publication Number WO 2018/048354 Al (51) International Patent Classification: C12Q 1/68 (2006.01) (21) International Application Number: PCT/SG2017/050448 (22) International Filing Date: 07 September 2017 (07.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10201607451Y 07 September 2016 (07.09.2016) SG 10201705058S 19 June 2017 (19.06.2017) SG (71) Applicants: AGENCY FOR SCIENCE, TECHNOLO- GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10, Connexis, Singapore 138632 (SG). TAN TOCK SENG HOSPITAL [SG/SG]; 11 Jalan Tan Tock Seng, Sin- gapore 308433 (SG). (72) Inventors: YU, Qiang; c/o Genome Institute of Singa- pore, 60 Biopolis Street, Singapore 138672 (SG). GOH, Man Yuan; c/o Genome Institute of Singapore, 60 Biopolis Street, Singapore 138672 (SG). FENG, Min; c/o Genome Institute of Singapore, 60 Biopolis Street, Singapore 138672 (SG). TAN, Ern Yu; c/o Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433 (SG). UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (74) Agent: DONALDSON & BURKINSHAW LLP; 24 Raf- fles Place, #15-00 Clifford Centre, Singapore 048621 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (54) Title: A METHOD OF IDENTIFYING RISK OF CANCER AND THERAPEUTIC OPTIONS (57) : There is provided a method of identifying risk of cancer in a human subject, the method comprising: determining in a biological sample of the subject, whether a copy number amplification of at least one continuous genomic region specific to human chromosome 1q21 is present, wherein the presence of a copy number amplification of the region specific to human chromosome 1q21 represents an elevated risk of cancer in the subject and the at least one continuous genomic region is selected from the group consisting of: a human TUFT1 gene or a gene from the human S100 family. It is also provided a method of treating cancer in a subject determined to have a copy number amplification of a region specific to human chromosome 1q21, the method comprising administering a therapeutic agent capable of suppressing IRAK1, IRAK4 or a S100 family member, such as Pacritinib. There are also provided a method of treating cancer, related polynucleotides, kits, therapeutic agents and use of the therapeutic agents. *t-C 00 O 00 O 0